Vera Therapeutics (VERA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
21 May, 2026Opening remarks and agenda
Meeting commenced at 8:00 A.M. Pacific Time on May 21st, 2026, via a virtual platform, with board members, executive team, and auditors present.
The agenda included three proposals: election of directors, ratification of auditors, and an advisory vote on executive compensation.
Voting procedures and rules of conduct were explained, with polls open for all matters.
Board and executive committee updates
Three nominees for Class II directors were presented: Michael Morrissey, Patrick Enright, and James Myers, to serve until the 2029 annual meeting.
Shareholder proposals
Three proposals were submitted: election of directors, ratification of KPMG LLP as auditors for 2026, and an advisory vote on executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vera Therapeutics
- TRUTAKNA launched after FDA accelerated approval; Q2 net loss $109.5M, cash $499.2M.VERA
Q2 2026 - Atacicept stabilized kidney function in IgA nephropathy; phase 3 data expected Q2 2025.VERA
7th Annual Evercore ISI HealthCONx Conference - TRUTAKNA delivers robust efficacy and safety in IgAN, targeting a major unmet market need.VERA
Corporate presentation - FDA accelerated approval for TRUTAKNA introduces a novel therapy for adults with IgA nephropathy.VERA
FDA announcement - Atacicept advanced toward FDA approval as net loss widened to $121M, with strong cash reserves.VERA
Q1 2026 - Atacicept nears FDA approval with strong data, broad label, and robust commercial launch plans.VERA
TD Cowen 46th Annual Health Care Conference - Atakicept shows strong efficacy and safety in IgAN, with launch and pipeline expansion imminent.VERA
Citi Annual Global Healthcare Conference 2025 - Atacicept nears pivotal data and broad expansion, targeting multiple autoimmune diseases.VERA
R&D Day 2024 - Atacicept achieved a 46% proteinuria reduction and strong safety in phase III IgAN trial.VERA
Study Result